What type of study is this?

This is a Literature Review study.

September 10, 2025RSC Medicinal ChemistryOpen Access

Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)

View Full Paper

Ask AI

Bookmark

The diversity of heterocycles is significant in new active substances approved by the EMA.
This analysis spans medicines approved from 2014 to 2023, showcasing structural variation.
Heterocycles contribute greatly to the complexity of pharmaceutical compounds in this period.
Understanding heterocycle diversity aids in the development of innovative pharmaceuticals.

Implication

This review examines heterocycle diversity in pharmaceuticals approved by the European Medicines Agency, indicating trends over a decade.

Abstract

This review presents a detailed analysis of the heterocycle diversity amongst medicines with new active substances (NAS) approved by the European Medicines Agency in the last 10 years (2014–2023). A...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ward et al. (2025) studied this question.

synapsesocial.com/papers/68c1c31254b1d3bfb60f051f https://doi.org/10.1039/d5md00403a

View Full Paper

Ask AI

Bookmark

Implication

This review examines heterocycle diversity in pharmaceuticals approved by the European Medicines Agency, indicating trends over a decade.

Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)

Key Points

Implication

Abstract

Discussion

Cite This Study

Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading